GSR and Behcet disease: These findings may support a new treatment strategy on gene expression changes in glutamatergic neurotransmission and GluR expression commonly identified among schizophrenia, BD, and MDD by GWAS, postmortem brain, and magnetic resonance spectroscopy studies (29–32).